FIELD: medicine.
SUBSTANCE: invention concerns a method for screening in vitro of potential drugs for treating tuberculosis by deranged arabinogalactan biosynthesis wherein said method involves the stage of contacting a cell culture Mycobacterium tuberculosis, overexpressing protein ensuring the transformation of decaprenyl-P-ribose into decaprenyl-P-arabinose, and which can be coded by rv3790 gene or its homologues, or an artificial open reading frame, an expression product which is identical to Rv3790 protein, or it is its homologue with a potential drug; it is followed by evaluating an inhibition percentage caused by the potential drug relative to controlling in the analytic test.
EFFECT: invention provides identification of the new drugs.
25 cl, 2 dwg, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOGENIC COMPOSITION (VERSIONS) BASED ON RECOMBINANT INTRACELLULAR PATHOGEN | 2003 |
|
RU2337707C2 |
| QUATERNARY AMMONIUM DERIVATIVES OF 2-AMINOTHIOPHEN-3-CARBOXYLATES HAVING ANTI-TUBERCULOSIS ACTIVITY | 2016 |
|
RU2629369C1 |
| PYRANOINDOLES WITH ANTI-TUBERCULOSIS ACTIVITY | 2018 |
|
RU2675240C1 |
| TEST SYSTEM OF Mycobacterium smegmatis aphVIII + FOR SCREENING OF INHIBITORS OF SERINE-THREONINE PROTEIN KINASES OF EUKARYOTIC TYPE | 2014 |
|
RU2566998C1 |
| STRAIN OF MYCOBACTERIUM TUBERCULOSIS BN FOR MODELLING LATENT TUBERCULOSIS INFECTION | 2021 |
|
RU2760751C1 |
| METHOD FOR INTRODUCING UNMARKED POINT SUBSTITUTIONS INTO THE CHROMOSOME OF MICROBACTERIA | 2020 |
|
RU2763746C1 |
| VACCINES OF RECOMBINANT INTRACELLULAR PATHOGENS AND USES THEREOF | 2001 |
|
RU2266132C2 |
| FURILIDENE FURANONE DERIVATIVES OF USNIC ACID AS NEW ANTITUBERCULOSIS AGENTS | 2013 |
|
RU2533707C1 |
| ANTITUBERCULOSIS REMEDY | 2017 |
|
RU2756208C2 |
| ANTIBACTERIAL COMPOUNDS AGAINST DRUG RESISTANT BACTERIA | 2014 |
|
RU2672064C2 |
